China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Jollibee Plans U.S. Listing for International Business, Shares Rally 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Embraer Boosts Aircraft Deliveries in Q4 2025, Signaling Strong Growth Into 2026 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
SEATTLE, Oct. 24, 2017 -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Scott D. Myers, President and Chief Executive Officer, will participate in two panel discussions in the month of November.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/02938d7b-513e-467d-b9af-44a422fc2a16
November 7-8, 2017
Boston Biotech Conferences NY/NJ CEO, Apella at Alexandria Center, NY, NY
Panel: State of the Markets: Biotech and Pharma
More information on the conference can be found at http://bbbiotechconference.com/ceo-meetings.php
November 13-14, 2017
YJP CEO Europe Forum in Berlin will feature a Healthcare Innovation Symposium
Panel: Transitioning from an R&D Company to a Commercial Venture
More information on YJP and this meeting can be found at http://access.yjp.org/e/er4ka_4
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib, is an investigational oral, selective small molecule kinase inhibitor that is highly selective for HER2 and the Company’s lead product in development for the treatment of HER2 overexpressing cancers. Cascadian Therapeutics is conducting a randomized, double-blind, controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab, in patients with locally advanced or metastatic HER2+ breast cancer with and without brain metastases, who have previously been treated with trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.HER2CLIMB.com or www.clinicaltrials.gov. For more information, please visit www.cascadianrx.com.
Investor and Media Contact:
Monique Greer
Cascadian Therapeutics
206-801-2107
[email protected]
